Clinical trials
Advanced Solid Tumor Cancer clinical trials
Below are recruiting advanced solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,335 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07417501RecruitingPhase 2
Lenvatinib plus immunotherapy for advanced cancers with 11q13 amplification
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
Wuhan, HubeiAges 18 years+ - NCT06819215RecruitingPhase 1/Phase 2
VB15010 for advanced solid tumors with HRR gene mutation
This trial tests an oral medication (VB15010) in people with advanced solid tumors that have a specific DNA repair gene mutation (called HRR mutation). The goal is to see if the drug can stop or slow down cancer growth.
Jinan, ShandongAges 18–75 - NCT06051760RecruitingPhase 1
NV-001 for advanced solid tumors after standard treatments
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06293651RecruitingPhase 1/Phase 2
Study of DA-4505 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called DA-4505, given alone or with another drug (pembrolizumab), for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against the cancer.
SeoulAges 18 years+ - NCT07414316RecruitingEarly Phase 1
GK01 cell therapy for advanced lung or esophageal cancer
This trial tests a new cell treatment called GK01 for people with advanced lung cancer or esophageal cancer that has not responded to standard treatments. The study aims to see if this therapy can help shrink tumors or slow the cancer's growth.
NanchangAges 18–75 - NCT07407933RecruitingPhase 1/Phase 2
YL201 with other cancer drugs for advanced solid tumors
This trial tests a new drug, YL201, combined with other cancer treatments for people with a certain type of advanced lung cancer (extensive-stage small cell lung cancer). It may help shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07408258RecruitingPhase 1
Safety and dosing study of ONC-783 for advanced solid tumors
This trial tests an experimental drug called ONC-783 for people with advanced pancreatic, ovarian, colorectal, or breast cancer. The goal is to see if the drug is safe, how it works in the body, and whether it can help shrink tumors.
New York, New YorkAges 18 years+ - NCT07413328RecruitingPhase 1
HWS116 for advanced solid tumors
This trial tests an experimental drug, HWS116, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07407504RecruitingPhase 1
Targeted therapy for cancers with a specific gene change
This trial tests an experimental drug called GenSci145, which may target cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07410676RecruitingPhase 1/Phase 2
Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges Any age - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Los Angeles, CaliforniaAges 18 years+ - NCT07405086RecruitingPhase 4
Morning versus afternoon immunotherapy for advanced cancer
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Portland, OregonAges 18 years+ - NCT07396584RecruitingPhase 1/Phase 2
HMPL-A580 for advanced or metastatic solid tumors
This trial tests a new drug called HMPL-A580 in people with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see if it is safe and effective.
Orange, CaliforniaAges 18 years+ - NCT07397338RecruitingPhase 1/Phase 2
RAS inhibitors with ivonescimab for solid tumors
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07389239RecruitingPhase 1/Phase 2
Immunotherapy for ovarian cancer and other advanced tumors
This study tests an immunotherapy treatment for people with advanced solid tumors, including ovarian cancer, sarcoma, prostate, breast, lung, and others. It is designed for tumors that show a specific marker called NY-ESO-1, and aims to see if the treatment can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT07387081RecruitingPhase 2
Study of LM-24C5 for advanced solid tumors
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Fuzhou, FujianAges 18–80 - NCT07387068RecruitingPhase 1
Testing GEN1079 for advanced solid tumors
This trial tests an experimental drug called GEN1079 for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if it's safe and if it helps shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07382531RecruitingPhase 1/Phase 2
OH2 and BS006 injection for advanced solid tumors
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Scottsdale, ArizonaAges 18 years+ - NCT07381829RecruitingPhase 1
HC010 plus chemotherapy for advanced lung cancer
This trial tests an experimental drug called HC010 combined with chemotherapy for people with advanced lung cancer, including certain types of non-small cell or small cell lung cancer. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07380386RecruitingPhase 1/Phase 2
SKB105 injection for advanced solid tumors
This trial tests a new drug called SKB105 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07382544RecruitingPhase 1
Study of BMS-986504 with olaparib for MTAP-loss cancers
This trial tests a combination of two drugs (BMS-986504 and olaparib) for people with advanced solid tumors that have a specific genetic change called MTAP loss. It aims to see if this combination can help when standard treatments have stopped working or aren't available.
Houston, TexasAges 18 years+
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor cancer?
- Yes. Clin2 currently lists 1,335 recruiting advanced solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.